New drug combo shows promise for Hard-to-Treat cancers
Disease control
Completed
This early-phase trial tested an experimental drug called LM-108, alone or combined with another immunotherapy, in 78 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers als…
Phase: PHASE1, PHASE2 • Sponsor: LaNova Australia Pty Limited • Aim: Disease control
Last updated Jun 26, 2026 15:31 UTC